Literature DB >> 12097566

Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production.

Hiroko Tomiyama1, Hirofumi Akari, Akio Adachi, Masafumi Takiguchi.   

Abstract

A previous study using a Nef-defective human immunodeficiency virus type 1 (HIV-1) mutant suggested that Nef-mediated down-regulation of HLA class I on the infected cell surface affects the cytolytic activity of HIV-1-specific cytotoxic T-lymphocyte (CTL) clones for HIV-1-infected primary CD4(+) T cells. We confirmed this effect by using a nef-mutant HIV-1 strain (NL-M20A) that expresses a Nef protein which does not induce down-regulation of HLA class I molecules but is otherwise functional. HIV-1-specific CTL clones were not able to kill primary CD4(+) T cells infected with a Nef-positive HIV-1 strain (NL-432) but efficiently lysed CD4(+) T cells infected with NL-M20A. Interestingly, CTL clones stimulated with NL-432-infected CD4(+) T cells were able to produce cytokines, albeit at a lower level than when stimulated with NL-M20A-infected CD4(+) T cells. This indicates that Nef-mediated HLA class I down-regulation affects CTL cytokine production to a lesser extent than cytolytic activity. Replication of NL-432 was partially suppressed in a coculture of HIV-1-infected CD4(+) T cells and HIV-1-specific CTL clones, while replication of NL-M20A was completely suppressed. These results suggest that HIV-1-specific CD8(+) T cells are able to partially suppress the replication of HIV-1 through production of soluble HIV-1-suppressive factors such as chemokines and gamma interferon. These findings may account for the mechanism whereby HIV-1-specific CD8(+) T cells are able to partially but not completely control HIV-1 replication in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097566      PMCID: PMC136399          DOI: 10.1128/jvi.76.15.7535-7543.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  Cellular immune response to human immunodeficiency virus.

Authors:  P J Norris; E S Rosenberg
Journal:  AIDS       Date:  2001-02       Impact factor: 4.177

3.  Downregulation of HLA class I antigens in HIV-1-infected cells.

Authors:  T Kerkau; R Schmitt-Landgraf; A Schimpl; E Wecker
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

4.  Down-modulation of MHC-I in a CD4+ T cell line, CEM-E5, after HIV-1 infection.

Authors:  J A Scheppler; J K Nicholson; D C Swan; A Ahmed-Ansari; J S McDougal
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

5.  Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS.

Authors:  S Carl; T C Greenough; M Krumbiegel; M Greenberg; J Skowronski; J L Sullivan; F Kirchhoff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Dendritic cells transduced with HIV Nef express normal levels of HLA-A and HLA-B class I molecules.

Authors:  L A Cramer; J A Frelinger
Journal:  J Acquir Immune Defic Syndr       Date:  2001-08-15       Impact factor: 3.731

7.  Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

Authors:  X Gao; G W Nelson; P Karacki; M P Martin; J Phair; R Kaslow; J J Goedert; S Buchbinder; K Hoots; D Vlahov; S J O'Brien; M Carrington
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

8.  Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individuals.

Authors:  F Puppo; S Brenci; O Bosco; L Lanza; S Barocci; A Nocera; M Ghio; P Contini; M Setti; M Scudeletti; F Indiveri
Journal:  AIDS Res Hum Retroviruses       Date:  1997-11-20       Impact factor: 2.205

9.  Inhibition of human immunodeficiency virus type 1 replication in primary CD4(+) T lymphocytes, monocytes, and dendritic cells by cytotoxic T lymphocytes.

Authors:  M E Severino; N V Sipsas; P T Nguyen; S A Kalams; B D Walker; R P Johnson; O O Yang
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

Authors:  V Appay; D F Nixon; S M Donahoe; G M Gillespie; T Dong; A King; G S Ogg; H M Spiegel; C Conlon; C A Spina; D V Havlir; D D Richman; A Waters; P Easterbrook; A J McMichael; S L Rowland-Jones
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  42 in total

1.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

2.  Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes.

Authors:  Tomohiro Akahoshi; Takayuki Chikata; Yoshiko Tamura; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

3.  Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101.

Authors:  Yuka Kawashima; Nozomi Kuse; Hiroyuki Gatanaga; Takuya Naruto; Mamoru Fujiwara; Sachi Dohki; Tomohiro Akahoshi; Katsumi Maenaka; Philip Goulder; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

4.  Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses.

Authors:  Hirokazu Koizumi; Masao Hashimoto; Mamoru Fujiwara; Hayato Murakoshi; Takayuki Chikata; Mohamed Ali Borghan; Atsuko Hachiya; Yuka Kawashima; Hiroshi Takata; Takamasa Ueno; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

5.  A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes.

Authors:  Sayuki Iijima; Young-Jung Lee; Hirotaka Ode; Stefan T Arold; Nobuyuki Kimura; Masaru Yokoyama; Hironori Sato; Yasuhito Tanaka; Klaus Strebel; Hirofumi Akari
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

6.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

Review 7.  HIV accessory proteins and surviving the host cell.

Authors:  Jenny L Anderson; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

8.  Pol-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation.

Authors:  Jonah B Sacha; Chungwon Chung; Jason Reed; Anna K Jonas; Alexander T Bean; Sean P Spencer; Wonhee Lee; Lara Vojnov; Richard Rudersdorf; Thomas C Friedrich; Nancy A Wilson; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

9.  Simultaneous assessment of CD4 and MHC-I downregulation by Nef primary isolates in the context of infection.

Authors:  Ayub Ali; Susan Realegeno; Otto O Yang; Martha J Lewis
Journal:  J Virol Methods       Date:  2009-07-28       Impact factor: 2.014

10.  Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts.

Authors:  Mamoru Fujiwara; Junko Tanuma; Hirokazu Koizumi; Yuka Kawashima; Kazutaka Honda; Saori Mastuoka-Aizawa; Sachi Dohki; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.